Preclinical Development of HIV-1 Vif Antagonists - Core B

我们的目标是确定HLV-1vif的新型拮抗剂，这需要四个不同机构的四名研究人员的努力。研究计划要求这些小组之间密切沟通，迅速交换数据、研究材料和试剂，并有能力征求科学咨询委员会(SAB)的意见并采取行动。这些活动将由行政核心协调。核心的主要职能包括： 协调项目负责人和SAB之间一年两次的面对面会议，以概述进展情况，为个别项目设定里程碑和行动事项。 维持对个别研究组成部分的预算监督，并在必要时根据SAB的建议重新分配资源。 通过电话会议促进参与该项目的调查人员之间的持续对话。 协调项目不同阶段的数据共享和材料交换。协调向国家卫生研究院提交的进度报告以及每年一次的国家卫生研究院实地考察。协调研究成果在科学会议上的陈述和研究成果的发表。 作为参与机构的商业风险投资和知识产权局的中间人，以及解决通过知识产权协议产生的任何问题。 Mario Stevenson博士将担任行政核心主任，并将由Maria Pieiga协助，Maria Pieiga作为传染病司司长，在监督NIH和行业资助项目方面拥有广泛的专业知识。

Our goal of identifying novel antagonists of HlV-1 vif involves the efforts of four investigators at four different institutions. The research plan requires close communication between these groups, rapid exchange of data, research materials and reagents as well the ability to solicit input from the Scientific Advisory Board (SAB) and act on that input. These activities will be coordinated by the Administrative Core. The major functions of the Core will include: Coordinate biannual, in-person meetings between project leaders and the SAB in order to overview progress, set milestones and action items for the individual projects. Maintain budgetary oversight for the individual research components and, if necessary reallocate resources if recommended by the SAB. Promote continuous dialog between investigators engaged in the project through teleconferencing. Coordinate data sharing and the exchange of materials at different stages in the project. Coordinate preparation of progress reports to the NIH as well as an annual NIH site-visit. Coordinate the presentation of research findings at scientific meetings and publication of research findings.. Serve as an intermediary with the Commercial Ventures and Intellectual Property office ofthe participating Institutions as well as for any issues that arise through intellectual property agreements. Mario Stevenson, Ph.D. will serve as Director ofthe Administrative Core and will be assisted by Maria Pieiga who, as Administrator ofthe Division of Infectious Diseases, has extensive expertise in the oversight of NIH and Industry-funded projects.